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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Finnish language. 
The reading comprehension of the questionnaire was tested in ten JIA parents and patients. Each participating centre was 
asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen 
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase 
explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling effects, 
internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and 
discriminant validity). A total of 173 JIA patients (1.2% systemic, 46.2% oligoarticular, 39.9% RF-negative polyarthritis, 
12.7% other categories) and 100 healthy children, were enrolled in five paediatric rheumatology centres. The JAMAR 
components discriminated well healthy subjects from JIA patients. All JAMAR components revealed good psychometric 
performances. In conclusion, the Finnish version of the JAMAR is a valid tool for the assessment of children with JIA and 
is suitable for use both in routine clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Finnish parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient-
reported outcomes in JIA, including overall well-being, 
functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the epidemiol-
ogy, outcome and treatment of childhood arthritis (EPOCA) 
in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Finnish language.
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Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from March 2012 to 
October 2013. Children were recruited after Ethics Commit-
tee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, 3 = unable to do and 
not applicable if it was not possible to answer the ques-
tion or the patient was unable to perform the task due 
to their young age or to reasons other than JIA. The 
total PF score ranges from 0 to 45 and has three com-
ponents: PF-lower limbs (PF-LL); PF-hand and wrist 
(PF-HW) and PF-upper segment (PF-US) each scoring 
from 0 to 15 [7]. Higher scores indicate higher degree 
of disability [8–10];
 2. rating of the intensity of the patient’s pain on a 21-num-
bered circle Visual Analogue Scale (VAS) [11];
 3. assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 4. assessment of morning stiffness (present/absent);
 5. assessment of extra-articular symptoms (fever and 
rash) (present/absent);
 6. rating of the level of disease activity on a 21-circle 
VAS;
 7. rating of disease status at the time of the visit (categori-
cal scale);
 8. rating of disease course from previous visit (categori-
cal scale);
 9. checklist of the medications the patient is taking (list 
of choices);
 10. checklist of side effects of medications;
 11. report of difficulties with medication administration 
(list of items);
 12. report of school/university/work problems caused by 
the disease (list of items);
 13. assessment of HRQoL, through the physical health 
(PhH), and psychosocial health (PsH) subscales (5 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14];
 14. rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 15. a question about satisfaction with the outcome of the 
illness (Yes/No) [15].
The JAMAR is available in three versions, one for par-
ent proxy-report (child’s age 2–18), one for child self-
report, with the suggested age range of 7–18 years, and 
one for adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to the international guidelines with 2–3 forward 
and backward translations. In those countries for which 
the translation of JAMAR had been already cross-cultur-
ally adapted in a similar language (i.e., Spanish in South 
American countries), only the probe technique was per-
formed. Reading comprehension and understanding of the 
translated questionnaires were tested in a probe sample of 
ten JIA parents and ten patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy chil-
dren and their parents.
The statistical validation phase explored the descrip-
tive statistics and the psychometric issues [16]. In par-
ticular, we evaluated the following validity components: 
the first Likert assumption [mean and standard deviation 
(SD) equivalence]; the second Likert assumption or equal 
item–scale correlations (Pearson r: all items within a scale 
should contribute equally to the total score); third Lik-
ert assumption (item internal consistency or linearity for 
which each item of a scale should be linearly related to the 
total score that is 90% of the items should have Pearson 
r ≥ 0.4); floor/ceiling effects (frequency of items at lower 
and higher extremes of the scales, respectively); internal 
consistency, measured by the Cronbach’s alpha, interscale 
correlation (the correlation between two scales should be 
lower than their reliability coefficients, as measured by 
Cronbach’s alpha); test–retest reliability or intra-class 
correlation coefficient (reproducibility of the JAMAR 
repeated after 1 or 2 weeks); and construct validity in its 
two components: the convergent or external validity which 
examines the correlation of the JAMAR subscales with the 
six JIA core set variables, with the addition of the parent 
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assessment of disease activity and pain by the Spearman’s 
correlation coefficients (r) [17] and the discriminant valid-
ity, which assesses whether the JAMAR discriminates 
between the different JIA categories and healthy children 
[18]. Quantitative data were reported as medians with 1st 
and 3rd quartiles and categorical data as absolute frequen-
cies and percentages.
The complete Finnish parent and patient versions of the 
JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Finnish JAMAR was fully cross-culturally adapted 
from the standard English version with three forward and 
two backward translations with concordance in 109/123 
translation lines (88.6%) for the parent version and 
108/120 lines (90%) for the child version.
Of the 123 lines in the parent version of the JAMAR, 
122 (99%) were understood by at least 80% of the 10 par-
ents tested (median = 100%; range 40–100%); 119/120 
(99%) lines of the patient version of the JAMAR were 
understood by at least 80% of the children (median = 100%; 
range 70–100%). Line 114 of parent version of the Finnish 
JAMAR and line 111 of the child version were modified 
according to parents/children suggestions after the probe 
technique.
Demographic and clinical characteristics 
of the subjects
A total of 173 JIA patients and 100 healthy children (total 
of 273 subjects) were enrolled at five paediatric rheuma-
tology centres.
In the 173 JIA subjects, the JIA categories were 1.2% 
with systemic arthritis, 46.2% with oligoarthritis, 39.9% 
with RF-negative polyarthritis, 0.6% with RF-positive 
polyarthritis, 0.6% with psoriatic arthritis, 7.5% with 
enthesitis-related arthritis and 4.0% with undifferentiated 
arthritis (Table 1).
A total of 265/273 (97.1%) subjects had the parent 
version of the JAMAR completed by a parent (165 from 
parents of JIA patients and 100 from parents of healthy 
children). The JAMAR was completed by 217/265 (81.9%) 
mothers and 48/265 (18.1%) fathers.
The child version of the JAMAR was completed by 
222/273 (81.3%) children aged 6.8 or older. In addition, 
patients younger than 7 years, capable to assess their per-
sonal condition and able to read and write, were asked to 
fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores (median (1st–3rd quartile)) obtained for the 
PF, the PhH, the PsH subscales and total score of the 
HRQoL scales. The JAMAR components discriminated 
well between healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing “Results” section refers mainly to the parent’s version of 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
For all JAMAR items, the median number of missing 
responses were 0.6% (0.0%-0.6%).
The response pattern for both PF and HRQoL was posi-
tively skewed toward normal functional ability and normal 
HRQoL.
All response choices were used for the different HRQoL 
items except for items 1, 2, 4, 6, 8 and 9, whereas a reduced 
number of response choices were used for all the PF items 
except for item 4. The mean and SD of the items within a 
scale were roughly equivalent for the PF and for the HRQoL 
items, except for HRQoL item 5 (data not shown). The 
median number of items marked as not applicable was 0% 
(0%-0%) for the PF and 1% (1%-6%) for the HRQoL.
Floor and ceiling effect
The median floor effect was 92.7% (89.7–93.9%) for the 
PF items, 69.7% (61.2–75.2%) for the HRQoL-PhH items, 
and 68.5% (67.3–69.7%) for the HRQoL-PsH items. The 
median ceiling effect was 0% (0–0%) for the PF items, 0.6% 
(0–2.4%) for the HRQoL-PhH items, and 0% (0–0.6%) for 
the HRQoL-PsH items. The median floor effect was 40.6% 
for the pain VAS, 33.9% for the disease activity VAS and 
34.5% for the well-being VAS. The median ceiling effect 
was 0% for the pain VAS, 0% for the disease activity VAS 
and 0% for the well-being VAS.
Equal item–scale correlations (second Likert 
assumption)
Pearson’s items–scale correlations corrected for overlap 
were roughly equivalent for items within a scale for 93% of 
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Table 1  Descriptive statistics (medians, 1st 3rd quartiles or absolute frequencies and %) for the 173 JIA patients
Data related to the JAMAR refers to the 165 JIA patients and to the 100 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS Visual Analogue 
Scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 
to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refers to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05 **p < 0.001 #p < 0.0001
Systemic Oligoarthritis RF − Polyar-
thritis
RF + Polyar-
thritis
Psoriatic 
arthritis
Enthesitis-
related 
arthritis
Undifferenti-
ated arthritis
All JIA 
patients
Healthy
N  = 2 N  =  80 N  = 69 N  = 1 N  = 1 N =  13 N  = 7 N  = 173 N  = 100
Female 1 (50%) 55 (68.8%) 51 (73.9%) 1 (100%) 0 (0%) 2 (15.4%) 4 (57.1%) 114 (65.9%)* 49 (49%)*
Age at visit 10 (9.8–10.1) 10.8 
(5.6–13.9)
9.4 (6.9–13.6) 16.1 (16.1–
16.1)
14.3 (14.3–
14.3)
13.3 (12.9–
15.1)
5.2 (4.3–13.1) 10.4 (6.8–
13.9)*
12.3 (11.3–
13.3)**
Age at onset 4.8 (4–5.6) 3.1 (1.9–5.3) 3.4 (2.3–6.3) 14.4 (14.4–
14.4)
2.5 (2.5–2.5) 8.7 (7.1–9.4) 1.7 (1.3–6) 3.4 (2.1–
6.8)**
Disease duration 5.2 (4.2–6.2) 4.9 (2.6–9.2) 4.9 (3.1–7.8) 1.7 (1.7–1.7) 11.8 (11.8–
11.8)
4.3 (3.4–6) 3.9 (2.6–7) 4.8 (2.7–8)
ESR 6 (2–10) 5 (2–8) 5 (2–7) 14 (14–14) 2 (2–2) 5 (2–7) 6 (5–14) 5 (2–8)
MD VAS 
(0–10 cm)
2 (0–4) 0 (0–0.8) 0 (0–1.5) 0 (0–0) 0 (0–0) 0 (0–1) 0 (0–2) 0 (0–1)
No. of swollen 
joints
0.5 (0–1) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–1) 0 (0–0)
No. of joints with 
pain
0.5 (0–1) 0 (0–0) 0 (0–1) 0 (0–0) 0 (0–0) 0 (0–3) 0 (0–0) 0 (0–0)
No. of joints with 
LOM
0.5 (0–1) 0 (0–1) 0 (0–2) 0 (0–0) 6 (6–6) 0 (0–1) 0 (0–1) 0 (0–1)
No. of active 
joints
0.5 (0–1) 0 (0–0) 0 (0–1) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–1) 0 (0–1)
Active systemic 
features
1 (50%) 1 (1.3%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (1.2%)
ANA status 0 (0%) 8 (10%) 5 (7.2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 13 (7.5%)
Uveitis 0 (0%) 26 (32.5%) 15 (22.1%) 0 (0%) 0 (0%) 0 (0%) 2 (28.6%) 43 (25%)
PF total score 0 (0–0) 0 (0–2) 0 (0–3) 0 (0–0) 0 (0–0) 0.5 (0–2.5) 0 (0–0) 0 (0–2) 0 (0–0)#
Pain VAS 3.5 (0–7) 1 (0–3) 1 (0–3) 1 (1–1) 0.5 (0.5–0.5) 0.5 (0–5.5) 0 (0–5) 0.5 (0–3) 0 (0–0)#
Disease activity 
VAS
3.8 (0–7.5) 1 (0–2.5) 1 (0–3) 1 (1–1) 0.5 (0.5–0.5) 0.8 (0–5) 0.3 (0–2) 1 (0–3)
Well-being VAS 3.8 (0–7.5) 1 (0–2) 1 (0–2) 1 (1–1) 1 (1–1) 0.5 (0–7) 0.3 (0–1) 1 (0–2) 0 (0–0)#
HRQoL PhH 1 (0–2) 1 (0–3) 1 (0–4) 1 (1–1) 0 (0–0) 0.5 (0–2.5) 2 (0–10) 1 (0–3) 0 (0–0)#
HRQoL-PsH 2 (1–3) 1 (0–2) 0 (0–2) 1 (1–1) 2 (2–2) 0 (0–3.5) 0.5 (0–3) 1 (0–2) 0 (0–1)#
HRQoL total 
score
3 (1–5) 3 (1–5) 2 (0–6) 2 (2–2) 2 (2–2) 1.5 (0–4.5) 3 (1–20) 3 (0–5) 0 (0–1)#
Pain/swell in > 1 
joint
1 (50%) 32/78 (41%) 25/65 (38.5%) 0 (0%) 1 (100%) 5/12 (41.7%) 3/6 (50%) 67/165 
(40.6%)
0 (0%)#
Morning stiff-
ness > 15 min
0 (0%) 16/78 (20.5%) 12/64 (18.8%) 0 (0%) 0 (0%) 4/12 (33.3%) 1/6 (16.7%) 33/164 
(20.1%)
0 (0%)#
Subjective remis-
sion
1 (50%) 38/78 (48.7%) 27/64 (42.2%) 0 (0%) 0 (0%) 4/12 (33.3%) 2/5 (40%) 72/163 
(44.2%)
In treatment 1 (50%) 65/78 (83.3%) 58/65 (89.2%) 1 (100%) 0 (0%) 10/12 (83.3%) 5/6 (83.3%) 140/165 
(84.8%)
Reporting side 
effects
1/1 (100%) 20/62 (32.3%) 24/58 (41.4%) 0 (0%) 0 (0%) 4/10 (40%) 3/5 (60%) 52/137 (38%)
Taking medication 
regularly
1/1 (100%) 55/65 (84.6%) 50/58 (86.2%) 1 (100%) 0 (0%) 8/10 (80%) 5/5 (100%) 120/140 
(85.7%)
With problems 
attending school
0 (0%) 6/43 (14%) 6/32 (18.8%) 0 (0%) 0 (0%) 2/11 (18.2%) 0 (0%) 14/91 (15.4%) 0 (0%)#
Satisfied with dis-
ease outcome
2 (100%) 70/77 (90.9%) 57/65 (87.7%) 1 (100%) 1 (100%) 8/11 (72.7%) 6/6 (100%) 145/163 
(89%)
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the PF items, with the exception of item 4 and for 80% of the 
HRQoL items, with the exception of items 1 and 7.
Items internal consistency (third Likert assumption)
Pearson’s item–scale correlations were ≥ 0.4 for 73% of 
items of the PF (except for PF items 11, 12, 13 and 15) and 
100% of items of the HRQoL.
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.82 for PF-LL, 0.81 for PF-HW, 0.45 
for PF-US. Cronbach’s alpha was 0.83 for HRQoL-PhH and 
0.81 for HRQoL-PsH.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS Visual Analogue Scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent N = 165/265 Child N = 122/222
Missing values (1st–3rd quartiles) 0.6% (0.0–0.6%) 0.0% (0.0–2.0%)
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 92.7% 95.1%
 HRQoL-PhH 69.7% 77.0%
 HRQoL-PsH 68.5% 68.9%
 Pain VAS 40.6% 41.0%
 Disease activity VAS 33.9% 36.1%
 Well-being VAS 34.5% 36.9%
Ceiling effect, median
 PF 0.0% 0.0%
 HRQoL-PhH 0.6% 0.0%
 HRQoL-PsH 0.0% 0.0%
 Pain VAS 0.0% 0.0%
 Disease activity VAS 0.0% 0.0%
 Well-being VAS 0.0% 0.8%
Items with equivalent item–scale correlation 93% for PF, 80% for HRQoL 100% for PF, 80% for HRQoL
Items with item–scale correlation ≥ 0.4 73% for PF, 100% for HRQoL 53% for PF, 90% for HRQoL
Cronbach’s alpha
 PF-LL 0.82 0.74
 PF-HW 0.81 0.88
 PF-US 0.45 0.46
 HRQoL-PhH 0.83 0.72
 HRQoL-PsH 0.81 0.78
Items with item–scale correlation lower than the Cronbach’s alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.98 0.23
 HRQoL-PhH 0.94 0.98
 HRQoL-PsH 0.91 0.91
Spearman’s correlation with JIA core set variables, median
 PF 0.4 0.3
 HRQoL-PhH 0.4 0.5
 HRQoL-PsH 0.1 0.4
 Pain VAS 0.3 0.2
 Disease activity VAS 0.3 0.3
 Well-being VAS 0.4 0.3
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Interscale correlation
The Pearson’s correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in eight JIA patients, by re-admin-
istering both versions (parent and child) of the JAMAR after 
a median of 6 days (range 6–7 days). The intraclass cor-
relation coefficients (ICC) for the PF total score showed an 
almost perfect reproducibility (ICC = 0.98). The ICC for the 
HRQoL-PhH and the ICC for the HRQoL-PsH showed an 
almost perfect reproducibility (ICC = 0.94 and ICC = 0.91, 
respectively).
Convergent validity
The Spearman’s correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.2 to 0.5 
(median = 0.4). The PF total score best correlation was 
observed with the parent assessment of pain (r = 0.54, 
p < 0.001). For the HRQoL, the median correlation of the 
PhH with the JIA core set of outcome variables ranged 
from 0.2 to 0.7 (median = 0.4), whereas for the PsH ranged 
from 0.04 to 0.4 (median = 0.1). The HRQoL-PhH showed 
the best correlation with the parent’s assessment of pain 
(r = 0.74, p < 0.001), while the HRQoL-PsH showed the best 
correlation with the parent global assessment of well-being 
(r = 0.49, p < 0.001). The median correlations between the 
pain VAS, the well-being VAS, and the disease activity VAS 
and the physician-centred and laboratory measures were 0.3 
(0.2–0.4), 0.3 (0.2–0.4), 0.4 (0.2–0.5), respectively.
Discussion
In this study, the Finnish version of the JAMAR was cross-
culturally adapted from the original standard English version 
with three forward and two backward translations. Accord-
ing to the results of the validation analysis, the Finnish par-
ent and patient versions of the JAMAR possess satisfactory 
psychometric properties. The disease-specific components 
of the questionnaire discriminated well between patients 
with JIA and healthy controls.
Psychometric performances were good for all domains of 
the JAMAR with few exceptions: 4 PF items (”Stretch out 
arms”, “Put hands behind neck”, “Turn head and look over 
shoulders” and “Bite into a sandwich or an apple”) showed 
a lower item internal consistency. However, the overall 
internal consistency was good for all the domains, except 
for PF-US that is poor.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from weak to moderate.
The results obtained for the parent version of the 
JAMAR are very similar to those obtained for the child 
version, which suggests that children are equally reli-
able proxy-reporters of their disease and health status as 
their parents. The JAMAR is aimed to evaluate the side 
effects of medications and school attendance, which are 
other dimensions of daily life that were not previously 
considered by other HRQoL tools. This may provide use-
ful information for intervention and follow-up in health 
care. In conclusion, the Finnish version of the JAMAR was 
found to have satisfactory psychometric properties and it 
is, thus, a reliable and valid tool for the multidimensional 
assessment of children with JIA.
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